Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies
Background/Objectives: Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes. Subjects/...
Saved in:
| Published in | International Journal of Obesity Vol. 40; no. 1; pp. 162 - 170 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.01.2016
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0307-0565 1476-5497 1476-5497 |
| DOI | 10.1038/ijo.2015.139 |
Cover
Loading…
| Abstract | Background/Objectives:
Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes.
Subjects/Methods:
From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals.
Results:
In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6±6.4 to 84.1±4.9 kg, change from baseline: −17.4±0.5 kg and −16.8±0.4%. WC in this group of patients decreased from 106.8±7.4 to 95.1±5.3 cm, change from baseline: −10.6±0.3 cm. BMI decreased from 32.69±1.4 to 27.07±1.57, change from baseline: −5.52±0.15 kg m
−2
. In patients with class II obesity, weight decreased from 116.8±6.9 to 91.3±6.3 kg, change from baseline: −25.3±0.5 kg and −21.5±0.4%. WC decreased from 113.5±7.5 to 100.0±5.4 cm, change from baseline: −13.9±0.4 cm. BMI decreased from 37.32±1.45 to 29.49±1.71, change from baseline: −8.15±0.17 kg m
−2
. In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg, change from baseline: −30.5±0.7 kg and −23.6±0.5%. WC decreased from 118.5±5.6 to 103.8±4.9 cm, change from baseline: −14.3±0.4 cm. BMI decreased from 41.93±1.48 to 32.46±1.59, change from baseline −9.96±0.29 kg m
−2
.
Conclusions:
Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. |
|---|---|
| AbstractList | Background/Objectives:
Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes.
Subjects/Methods:
From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals.
Results:
In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6±6.4 to 84.1±4.9 kg, change from baseline: −17.4±0.5 kg and −16.8±0.4%. WC in this group of patients decreased from 106.8±7.4 to 95.1±5.3 cm, change from baseline: −10.6±0.3 cm. BMI decreased from 32.69±1.4 to 27.07±1.57, change from baseline: −5.52±0.15 kg m
−2
. In patients with class II obesity, weight decreased from 116.8±6.9 to 91.3±6.3 kg, change from baseline: −25.3±0.5 kg and −21.5±0.4%. WC decreased from 113.5±7.5 to 100.0±5.4 cm, change from baseline: −13.9±0.4 cm. BMI decreased from 37.32±1.45 to 29.49±1.71, change from baseline: −8.15±0.17 kg m
−2
. In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg, change from baseline: −30.5±0.7 kg and −23.6±0.5%. WC decreased from 118.5±5.6 to 103.8±4.9 cm, change from baseline: −14.3±0.4 cm. BMI decreased from 41.93±1.48 to 32.46±1.59, change from baseline −9.96±0.29 kg m
−2
.
Conclusions:
Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes.BACKGROUND/OBJECTIVESLong-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes.From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals.SUBJECTS/METHODSFrom two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals.In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6±6.4 to 84.1±4.9 kg, change from baseline: -17.4±0.5 kg and -16.8±0.4%. WC in this group of patients decreased from 106.8±7.4 to 95.1±5.3 cm, change from baseline: -10.6±0.3 cm. BMI decreased from 32.69±1.4 to 27.07±1.57, change from baseline: -5.52±0.15 kg m(-2). In patients with class II obesity, weight decreased from 116.8±6.9 to 91.3±6.3 kg, change from baseline: -25.3±0.5 kg and -21.5±0.4%. WC decreased from 113.5±7.5 to 100.0±5.4 cm, change from baseline: -13.9±0.4 cm. BMI decreased from 37.32±1.45 to 29.49±1.71, change from baseline: -8.15±0.17 kg m(-2). In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg, change from baseline: -30.5±0.7 kg and -23.6±0.5%. WC decreased from 118.5±5.6 to 103.8±4.9 cm, change from baseline: -14.3±0.4 cm. BMI decreased from 41.93±1.48 to 32.46±1.59, change from baseline -9.96±0.29 kg m(-2).RESULTSIn all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6±6.4 to 84.1±4.9 kg, change from baseline: -17.4±0.5 kg and -16.8±0.4%. WC in this group of patients decreased from 106.8±7.4 to 95.1±5.3 cm, change from baseline: -10.6±0.3 cm. BMI decreased from 32.69±1.4 to 27.07±1.57, change from baseline: -5.52±0.15 kg m(-2). In patients with class II obesity, weight decreased from 116.8±6.9 to 91.3±6.3 kg, change from baseline: -25.3±0.5 kg and -21.5±0.4%. WC decreased from 113.5±7.5 to 100.0±5.4 cm, change from baseline: -13.9±0.4 cm. BMI decreased from 37.32±1.45 to 29.49±1.71, change from baseline: -8.15±0.17 kg m(-2). In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg, change from baseline: -30.5±0.7 kg and -23.6±0.5%. WC decreased from 118.5±5.6 to 103.8±4.9 cm, change from baseline: -14.3±0.4 cm. BMI decreased from 41.93±1.48 to 32.46±1.59, change from baseline -9.96±0.29 kg m(-2).Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men.CONCLUSIONSTestosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. BACKGROUND/OBJECTIVES: Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes. SUBJECTS/METHODS: From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals. RESULTS: In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6 [+ or -] 6.4 to 84.1 [+ or -] 4.9 kg, change from baseline: -17.4 [+ or -] 0.5 kg and -16.8 [+ or -] 0.4%. WC in this group of patients decreased from 106.8 [+ or -] 7.4 to 95.1 [+ or -] 5.3 cm, change from baseline: - 10.6 [+ or -] 0.3cm. BMI decreased from 32.69 [+ or -] 1.4 to 27.07 [+ or -] 1.57, change from baseline: -5.52 [+ or -] 0.15 kg m-2. In patients with class II obesity, weight decreased from 116.8 [+ or -] 6.9 to 91.3 [+ or -] 6.3 kg, change from baseline: -25.3 [+ or -] 0.5 kg and -21.5 [+ or -] 0.4%. WC decreased from 113.5 [+ or -] 7.5 to 100.0 [+ or -] 5.4 cm, change from baseline: -13.9 [+ or -] 0.4 cm. BMI decreased from 37.32 [+ or -] 1.45 to 29.49 [+ or -] 1.71, change from baseline: -8.15 [+ or -] 0.17 kg [m.sup.-2]. In patients with class III obesity, weight decreased from 129.0 [+ or -] 5.6 to 98.9 [+ or -] 4.8 kg, change from baseline: -30.5 [+ or -] 0.7 kg and -23.6 [+ or -] 0.5%. WC decreased from 118.5 [+ or -] 5.6 to 103.8 [+ or -] 4.9 cm, change from baseline: -14.3 [+ or -] 0.4 cm. BMI decreased from 41.93 [+ or -] 1.48 to 32.46 [+ or -] 1.59, change from baseline -9.96 [+ or -] 0.29 kg [m.sup.-2]. CONCLUSIONS: Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. International Journal of Obesity (2016) 40, 162-170; doi:10.1038/ijo.2015.139 Background/Objectives:Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes.Subjects/Methods:From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals.Results:In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6±6.4 to 84.1±4.9 kg, change from baseline: -17.4±0.5 kg and -16.8±0.4%. WC in this group of patients decreased from 106.8±7.4 to 95.1±5.3 cm, change from baseline: -10.6±0.3 cm. BMI decreased from 32.69±1.4 to 27.07±1.57, change from baseline: -5.52±0.15 kg m-2 . In patients with class II obesity, weight decreased from 116.8±6.9 to 91.3±6.3 kg, change from baseline: -25.3±0.5 kg and -21.5±0.4%. WC decreased from 113.5±7.5 to 100.0±5.4 cm, change from baseline: -13.9±0.4 cm. BMI decreased from 37.32±1.45 to 29.49±1.71, change from baseline: -8.15±0.17 kg m-2 . In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg, change from baseline: -30.5±0.7 kg and -23.6±0.5%. WC decreased from 118.5±5.6 to 103.8±4.9 cm, change from baseline: -14.3±0.4 cm. BMI decreased from 41.93±1.48 to 32.46±1.59, change from baseline -9.96±0.29 kg m-2 .Conclusions:Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. SUBJECTS/METHODS: From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals. International Journal of Obesity (2016) 40, 162-170; doi:10.1038/ijo.2015.139 Background/ Objectives: Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes.Subjects/ Methods: From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals. Results: In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6 plus or minus 6.4 to 84.1 plus or minus 4.9 kg, change from baseline: -17.4 plus or minus 0.5 kg and -16.8 plus or minus 0.4%. WC in this group of patients decreased from 106.8 plus or minus 7.4 to 95.1 plus or minus 5.3 cm, change from baseline: -10.6 plus or minus 0.3 cm. BMI decreased from 32.69 plus or minus 1.4 to 27.07 plus or minus 1.57, change from baseline: -5.52 plus or minus 0.15 kg m super(-2). In patients with class II obesity, weight decreased from 116.8 plus or minus 6.9 to 91.3 plus or minus 6.3 kg, change from baseline: -25.3 plus or minus 0.5 kg and -21.5 plus or minus 0.4%. WC decreased from 113.5 plus or minus 7.5 to 100.0 plus or minus 5.4 cm, change from baseline: -13.9 plus or minus 0.4 cm. BMI decreased from 37.32 plus or minus 1.45 to 29.49 plus or minus 1.71, change from baseline: -8.15 plus or minus 0.17 kg m super(-2). In patients with class III obesity, weight decreased from 129.0 plus or minus 5.6 to 98.9 plus or minus 4.8 kg, change from baseline: -30.5 plus or minus 0.7 kg and -23.6 plus or minus 0.5%. WC decreased from 118.5 plus or minus 5.6 to 103.8 plus or minus 4.9 cm, change from baseline: -14.3 plus or minus 0.4 cm. BMI decreased from 41.93 plus or minus 1.48 to 32.46 plus or minus 1.59, change from baseline -9.96 plus or minus 0.29 kg m super(-2). Conclusions: Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This study investigated effects of long-term TRT up to 8 years in hypogonadal men with different obesity classes. From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The effects of TRT on anthropometric as well as metabolic parameters were studied for a maximum duration of 8 years, mean follow-up: 6 years. All men received long-acting injections of testosterone undecanoate in 3-monthly intervals. In all three classes of obesity, T therapy produced significant WL, decrease in waist circumference (WC) and body mass index (BMI). In patients with class I obesity, mean weight decreased from 102.6±6.4 to 84.1±4.9 kg, change from baseline: -17.4±0.5 kg and -16.8±0.4%. WC in this group of patients decreased from 106.8±7.4 to 95.1±5.3 cm, change from baseline: -10.6±0.3 cm. BMI decreased from 32.69±1.4 to 27.07±1.57, change from baseline: -5.52±0.15 kg m(-2). In patients with class II obesity, weight decreased from 116.8±6.9 to 91.3±6.3 kg, change from baseline: -25.3±0.5 kg and -21.5±0.4%. WC decreased from 113.5±7.5 to 100.0±5.4 cm, change from baseline: -13.9±0.4 cm. BMI decreased from 37.32±1.45 to 29.49±1.71, change from baseline: -8.15±0.17 kg m(-2). In patients with class III obesity, weight decreased from 129.0±5.6 to 98.9±4.8 kg, change from baseline: -30.5±0.7 kg and -23.6±0.5%. WC decreased from 118.5±5.6 to 103.8±4.9 cm, change from baseline: -14.3±0.4 cm. BMI decreased from 41.93±1.48 to 32.46±1.59, change from baseline -9.96±0.29 kg m(-2). Testosterone therapy appears to be an effective approach to achieve sustained WL in obese hypogonadal men irrespective of severity of obesity. Based on these findings we suggest that T therapy offers safe and effective treatment strategy of obesity in hypogonadal men. |
| Audience | Academic |
| Author | Yassin, A Saad, F Haider, A Doros, G |
| Author_xml | – sequence: 1 givenname: F surname: Saad fullname: Saad, F email: farid.saad@bayer.com organization: Global Medical Affairs Andrology, Bayer Pharma, Department of Urology, Gulf Medical University – sequence: 2 givenname: A surname: Yassin fullname: Yassin, A organization: Department of Urology, Gulf Medical University, Institute for Urology and Andrology, Segeberger Kliniken, Department of Preventive Medicine, Men's Health Program, Dresden International University – sequence: 3 givenname: G surname: Doros fullname: Doros, G organization: Department for Epidemiology and Statistics, Boston University School of Public Health – sequence: 4 givenname: A surname: Haider fullname: Haider, A organization: Private Urology Practice |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26219417$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkkFrGzEQhZeS0jhpbz0XQaH00HUlrbTazaEQQtoaAr20ZyFrZ9cy65UraWPcf9R_2XGcBjukUHQQjL55I968s-xk8ANk2WtGp4wW1Ue39FNOmZyyon6WTZhQZS5FrU6yCS2oyqks5Wl2FuOSUiol5S-yU15yVgumJtnv67YFmyLxLen90OUJwoqkACatYEhk49KCJIjJR3zBycQPZAOuWyRihoZsjIuJRPcLiBuIYIwstmvf-cE0picosVfwc4gubYntTYwQySyfzWYXWI4Qbk1yyPekMcmQNnicv_EkQIfSYUtiGhsH8WX2vDV9hFf393n24_P196uv-c23L7Ory5vclpKlXNVAaaVsI6lqeD1vG1FXdm45pxWXc8UULQthuGgsL5RsoVEwp9DYWtKCl7Y4zz7tddfjfIV1dCGYXq-DW5mw1d44ffwyuIXu_K0WinMuKAq8vxcI_ueI1umVixb63gzgx6iZKmWtqqri_4FKQatKFTvVt4_QpR8D2nZHSYFq4oDqTA_aDa3HL9qdqL4UAvdfFbJEavoEhaeBlbO45NZh_ajh3UHDAkyfFtH3425x8Rh8c2jeg2t_A4fAhz1gg48xQPuAMKp3edaYZ73Ls8Y8I84f4dalu7zgj13_r6Z83xRRe-ggHFj1FP8Hh3oH3w |
| CitedBy_id | crossref_primary_10_1530_EDM_17_0084 crossref_primary_10_1089_andro_2020_0019 crossref_primary_10_5534_wjmh_180026 crossref_primary_10_1016_j_sxmr_2017_10_001 crossref_primary_10_1016_j_mayocp_2024_08_008 crossref_primary_10_1080_13685538_2016_1271783 crossref_primary_10_3389_fendo_2018_00769 crossref_primary_10_1089_andro_2020_0011 crossref_primary_10_1080_13685538_2019_1575354 crossref_primary_10_1111_obr_13429 crossref_primary_10_1080_13685538_2020_1867094 crossref_primary_10_1155_2016_1416503 crossref_primary_10_1515_hmbci_2017_0015 crossref_primary_10_1038_ijo_2016_148 crossref_primary_10_1089_andro_2020_0010 crossref_primary_10_1507_endocrj_EJ16_0195 crossref_primary_10_4103_jpgm_JPGM_887_20 crossref_primary_10_1111_andr_13544 crossref_primary_10_1080_14740338_2018_1424831 crossref_primary_10_1111_and_12768 crossref_primary_10_3389_fmed_2018_00190 crossref_primary_10_1080_13685538_2019_1578739 crossref_primary_10_2147_VHRM_S309714 crossref_primary_10_4103_aja202195 crossref_primary_10_1159_000499978 crossref_primary_10_1038_s41366_018_0105_2 crossref_primary_10_1038_ijir_2017_6 crossref_primary_10_17925_EE_2019_15_2_83 crossref_primary_10_1155_2017_4547658 crossref_primary_10_5115_acb_23_196 crossref_primary_10_17352_2455_8583_000043 crossref_primary_10_1111_dom_14206 crossref_primary_10_1016_j_ejphar_2025_177516 crossref_primary_10_1016_j_mce_2020_110945 crossref_primary_10_1007_s40618_016_0480_2 crossref_primary_10_1038_nrurol_2015_238 crossref_primary_10_1007_s40618_020_01381_8 crossref_primary_10_1080_13685538_2024_2357548 crossref_primary_10_1007_s11695_019_03829_0 crossref_primary_10_1038_s41366_019_0517_7 crossref_primary_10_1111_andr_12705 crossref_primary_10_1016_j_purol_2020_09_026 crossref_primary_10_1111_cen_13723 crossref_primary_10_1530_JOE_16_0002 crossref_primary_10_1080_2090598X_2021_1959261 crossref_primary_10_23736_S0031_0808_18_03513_9 crossref_primary_10_1080_13685538_2020_1763293 crossref_primary_10_1080_13685538_2022_2099828 crossref_primary_10_4111_icu_2016_57_6_384 crossref_primary_10_3389_fendo_2023_1267170 crossref_primary_10_1016_j_sxmr_2019_06_003 crossref_primary_10_1177_2050313X18823454 crossref_primary_10_3390_ijms17122125 crossref_primary_10_1080_13685538_2018_1509206 crossref_primary_10_3109_13685538_2015_1126573 crossref_primary_10_1111_bju_13578 crossref_primary_10_1053_j_jrn_2017_01_023 crossref_primary_10_1111_obr_12836 crossref_primary_10_1155_2022_8509204 crossref_primary_10_1016_j_sxmr_2016_06_002 crossref_primary_10_1080_00325481_2023_2172914 crossref_primary_10_14341_brh12711 crossref_primary_10_1111_and_13035 crossref_primary_10_1038_ijo_2016_242 crossref_primary_10_1177_1074248417691136 crossref_primary_10_1111_obr_12633 crossref_primary_10_1080_13685538_2018_1528445 crossref_primary_10_1111_cen_13113 crossref_primary_10_1016_j_sexol_2021_06_003 crossref_primary_10_1080_13685538_2016_1260107 crossref_primary_10_4158_EP161365_GL crossref_primary_10_1007_s12020_017_1516_x crossref_primary_10_1210_js_2017_00062 crossref_primary_10_2337_dc18_2388 crossref_primary_10_1530_JOE_17_0606 crossref_primary_10_30841_2307_5090_4_2022_274432 crossref_primary_10_1016_j_jcjd_2017_10_035 crossref_primary_10_1080_13685538_2017_1364234 crossref_primary_10_1016_j_jsxm_2020_10_019 crossref_primary_10_1152_ajpendo_00104_2023 crossref_primary_10_1111_and_12630 crossref_primary_10_1097_MD_0000000000010482 crossref_primary_10_1111_and_12514 crossref_primary_10_1080_13685538_2018_1524456 crossref_primary_10_4111_icu_2018_59_6_399 crossref_primary_10_1111_and_12633 crossref_primary_10_1016_j_exger_2017_08_016 crossref_primary_10_3390_biom11030372 crossref_primary_10_1152_ajpregu_00174_2016 crossref_primary_10_1177_03000605211002681 crossref_primary_10_1016_j_jsxm_2017_07_004 |
| Cites_doi | 10.2337/dc06-1426 10.1111/jsm.12404 10.1002/oby.20394 10.1186/1475-2840-13-36 10.1007/s11906-013-0343-6 10.1111/ijcp.12235 10.2147/CIA.S32036 10.1517/14656566.2014.890590 10.1016/j.eururo.2013.08.015 10.4111/kju.2015.56.4.310 10.1001/jama.2011.1914 10.1016/S2213-8587(14)70103-2 10.1111/dom.12012 10.1111/j.1365-2265.2010.03845.x 10.1111/j.1439-0272.2009.00991.x 10.7326/0003-4819-157-5-201209040-00475 10.3109/13685538.2012.699562 10.1056/NEJMoa1206168 10.1111/j.1743-6109.2012.02853.x 10.1016/j.eururo.2008.09.024 10.1002/oby.20407 10.1530/eje.1.02166 10.1001/jama.2014.5988 10.1038/oby.2008.290 10.1152/ajpendo.00592.2013 10.1530/EJE-12-0997 10.3109/13685538.2013.858113 10.1136/heartjnl-2014-306238 10.1038/ijo.2011.158 10.1111/j.1463-1326.2010.01256.x 10.1056/NEJMoa1112082 10.3945/ajcn.113.070052 10.2174/157339912799424573 10.1007/s40618-014-0066-9 10.1111/j.1743-6109.2010.01931.x 10.1007/s11695-014-1233-y 10.1016/j.orcp.2013.10.005 10.1016/j.mayocp.2014.10.011 10.1016/S0140-6736(09)61457-4 10.1097/MED.0000000000000086 10.3109/13685538.2011.631230 10.3109/13685538.2013.773420 10.1016/j.eururo.2012.06.027 10.1016/j.juro.2014.06.071 10.1186/1472-6823-11-18 10.1111/cob.12022 10.1001/jamasurg.2013.3654 10.1056/NEJMoa066254 10.1001/jama.2014.16968 10.1161/CIRCULATIONAHA.111.039453 10.1155/2014/527470 10.2164/jandrol.108.007005 10.1097/SLA.0b013e3182a5034b 10.1038/ijir.2008.19 10.1097/MED.0b013e3283398ee2 10.1007/s11695-012-0734-9 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2016 COPYRIGHT 2016 Nature Publishing Group Copyright Nature Publishing Group Jan 2016 Copyright © 2016 Macmillan Publishers Limited 2016 Macmillan Publishers Limited |
| Copyright_xml | – notice: The Author(s) 2016 – notice: COPYRIGHT 2016 Nature Publishing Group – notice: Copyright Nature Publishing Group Jan 2016 – notice: Copyright © 2016 Macmillan Publishers Limited 2016 Macmillan Publishers Limited |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T2 7TK 7TS 7X2 7X7 7XB 88E 88G 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA ATCPS AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0K M0S M1P M2M M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1038/ijo.2015.139 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) Neurosciences Abstracts Physical Education Index Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest Public Health Database (NC LIVE) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Database ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Agricultural Science Database Health & Medical Collection (Alumni) Medical Database ProQuest Psychology Database (NC LIVE) Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China Physical Education Index Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Agricultural & Environmental Science Collection Biological Science Collection Health & Safety Science Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Agricultural Science Database Health & Safety Science Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health Diet & Clinical Nutrition Recreation & Sports |
| DocumentTitleAlternate | Effects of long-term treatment with testosterone |
| EISSN | 1476-5497 |
| EndPage | 170 |
| ExternalDocumentID | PMC4722240 3916588311 A440058356 26219417 10_1038_ijo_2015_139 |
| Genre | Journal Article Observational Study |
| GeographicLocations | Germany United States--US |
| GeographicLocations_xml | – name: Germany – name: United States--US |
| GroupedDBID | .55 .GJ 29J 36B 39C 5RE 7X2 7X7 8R4 8R5 A8Z ABDBF ABOCM ABUWG ACUHS ADBBV AFFNX AI. ALMA_UNASSIGNED_HOLDINGS ATCPS AZQEC B0M BAWUL BENPR BHPHI BPHCQ C6C DIK DWQXO EAD EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P FYUFA GNUQQ HCIFZ IAO IHR ITC J5H M0K M1P M2M MVM NAO OK1 Q2X RNT RNTTT SV3 TUS VH1 WH7 X7M ZGI ZXP ~8M AAYXX CITATION --- -Q- ..I .L3 .XZ 0R~ 1CY 2FS 2WC 3V. 4.4 406 53G 5GY 70F 88E 8AO 8C1 8FE 8FH 8FI 8FJ AACDK AAHBH AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABAWZ ABCQX ABIVO ABJNI ABLJU ABZZP ACAOD ACGFS ACKTT ACPRK ACRQY ACZOJ ADHDB ADHUB AEFQL AEJRE AEMSY AENEX AEUYN AEVLU AEXYK AFBBN AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV AMYLF APEBS AXYYD BBNVY BKKNO BVXVI CCPQU CGR CS3 CUY CVF DNIVK DPUIP DU5 E3Z EBLON ECM EE. EIF EIOEI EJD FDQFY FERAY FIGPU FIZPM FSGXE HMCUK HZ~ IHW INH INR IPY IWAJR JSO JZLTJ KQ8 L7B M7P NPM NQJWS O9- OVD P2P P6G PKN PQQKQ PROAC PSQYO PSYQQ RNS ROL SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG UKHRP YCJ ~KM 7T2 7TK 7TS 7XB 8FK C1K K9. LK8 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA 5PM |
| ID | FETCH-LOGICAL-c651t-79e0087cd507d29bfd498cbc220825b7170634a24dc2375fed7eb0edc950326c3 |
| IEDL.DBID | C6C |
| ISSN | 0307-0565 1476-5497 |
| IngestDate | Thu Aug 21 18:06:03 EDT 2025 Fri Jul 11 11:22:37 EDT 2025 Fri Jul 11 04:17:14 EDT 2025 Sat Aug 23 12:48:14 EDT 2025 Tue Jun 17 21:32:11 EDT 2025 Tue Jun 10 20:27:58 EDT 2025 Thu May 22 21:19:44 EDT 2025 Wed Feb 19 01:57:56 EST 2025 Thu Apr 24 23:11:37 EDT 2025 Thu Jul 03 08:39:56 EDT 2025 Fri Feb 21 02:39:07 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c651t-79e0087cd507d29bfd498cbc220825b7170634a24dc2375fed7eb0edc950326c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.nature.com/articles/ijo.2015.139 |
| PMID | 26219417 |
| PQID | 1755482340 |
| PQPubID | 38864 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4722240 proquest_miscellaneous_1765978882 proquest_miscellaneous_1754088730 proquest_journals_1755482340 gale_infotracmisc_A440058356 gale_infotracacademiconefile_A440058356 gale_healthsolutions_A440058356 pubmed_primary_26219417 crossref_primary_10_1038_ijo_2015_139 crossref_citationtrail_10_1038_ijo_2015_139 springer_journals_10_1038_ijo_2015_139 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-01 |
| PublicationDateYYYYMMDD | 2016-01-01 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationSubtitle | Official journal of the International Association for the Study of Obesity |
| PublicationTitle | International Journal of Obesity |
| PublicationTitleAbbrev | Int J Obes |
| PublicationTitleAlternate | Int J Obes (Lond) |
| PublicationYear | 2016 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | SjöströmLNarbroKSjöströmCDKarasonKLarssonBWedelHSwedish obese subjects study. Effect of bariatric surgery on mortality in Swedish obese subjectsN Engl J Med200735774177210.1056/NEJMoa06625417715408 GaddeKMCurrent pharmacotherapy for obesity: extrapolation of clinical trials data to practiceExpert Opin Pharmacother2014158098221:CAS:528:DC%2BC2cXkvVyrtrc%3D10.1517/14656566.2014.89059024548209 SaadFHaiderADorosGTraishALong-term treatment of hypogonadal men with testosterone produces substantial and sustained weight lossObesity (Silver Spring)201321197519811:CAS:528:DC%2BC3sXhs1SmtLfJ10.1002/oby.20407 AversaABruzzichesRFrancomanoDRosanoGIsidoriAMLenziAEffects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled studyJ Sex Med20107349535031:CAS:528:DC%2BC3cXhsFemu7bE10.1111/j.1743-6109.2010.01931.x20646185 ZitzmannMMatternAHanischJGoorenLJonesHMaggiMIPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 menJ Sex Med2013105795881:CAS:528:DC%2BC3sXjsVWhtLs%3D10.1111/j.1743-6109.2012.02853.x22812645 DysonPAThe therapeutics of lifestyle management on obesityDiabetes Obes Metab2010129419461:STN:280:DC%2BC3cfmtFSqtw%3D%3D10.1111/j.1463-1326.2010.01256.x20880340 HackettGColeNBhartiaMKennedyDRajuJWilkinsonPThe response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study)Int J Clin Pract2014682032151:CAS:528:DC%2BC2cXhsF2rtLo%3D10.1111/ijcp.1223524355040 CalderónBGaldónACalañasAPeromingoRGalindoJGarcía-MorenoFEffects of bariatric surgery on male obesity-associated secondary hypogonadism: comparison of laparoscopic gastric bypass with restrictive proceduresObes Surg2014241686169210.1007/s11695-014-1233-y24664512 HeufelderAESaadFBunckMCGoorenLFifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosteroneJ Androl2009307267331:CAS:528:DC%2BD1MXhsVeru73N10.2164/jandrol.108.00700519578132 HaiderAZitzmannMDorosGIsbarnHHammererPYassinAIncidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registriesJ Urol2015193808610.1016/j.juro.2014.06.07124980615 HackettGColeNBhartiaMKennedyDRajuJWilkinsonPTestosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST StudyJ Sex Med2014118408561:CAS:528:DC%2BC2cXjvVyntrk%3D10.1111/jsm.1240424308723 Diabetes Prevention Program Research Group10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyLancet20093741677168610.1016/S0140-6736(09)61457-43135022 JohanssonKNeoviusMHemmingssonEEffects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trialsAm J Clin Nutr20149914231:CAS:528:DC%2BC2cXislantQ%3D%3D10.3945/ajcn.113.07005224172297 TraishAMTestosterone and weight loss: the evidenceCurr Opin Endocrinol Diabetes Obes2014213133221:CAS:528:DC%2BC2cXhsVOntLjO10.1097/MED.0000000000000086251059984154787 SvartbergJAgledahlIFigenschauYSildnesTWaterlooKJordeRTestosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hipInt J Impot Res2008203783871:CAS:528:DC%2BD1cXosVyiur0%3D10.1038/ijir.2008.1918480825 RyanDHBrayGAPharmacologic treatment options for obesity: what is old is new againCurr Hypertens Rep2013151821891:CAS:528:DC%2BC3sXnsFGjtrc%3D10.1007/s11906-013-0343-623625271 Look AHEAD Research GroupLook AHEAD Research GroupWingRRLong-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trialArch Intern Med201017015661575 BhattacharyaRKKheraMBlickGKushnerHMinerMMTestosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS)Clin Interv Aging201273213301:CAS:528:DC%2BC38XhsVSjtLnK10.2147/CIA.S32036229568673430096 MorgentalerATraishAMShifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growthEur Urol20095531032010.1016/j.eururo.2008.09.02418838208 BorstSEYarrowJFConoverCFNseyoUMeulemanJRLipinskaJAMusculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trialAm J Physiol Endocrinol Metab2014306E433E4421:CAS:528:DC%2BC2cXjs1yntbo%3D10.1152/ajpendo.00592.201324326421 KapoorDAldredHClarkSChannerKSJonesTHClinical and biochemical assessment of hypogonadism in men with type 2 diabetesDiabetes Care2007309119171:CAS:528:DC%2BD2sXkvVOgu7g%3D10.2337/dc06-142617392552 MoyerVAScreening for and management of obesity in adults: U.S. Preventive Services Task Force RecommendationAnn Intern Med201215737337822733087 FrancomanoDBruzzichesRBarbaroGLenziAAversaAEffects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot studyJ Endocrinol Invest2014374014111:CAS:528:DC%2BC28Xhsl2isbY%3D10.1007/s40618-014-0066-924639122 AversaABruzzichesRFrancomanoDGrecoEAFornariRDi LuigiLEffects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled studyAging Male201215961021:CAS:528:DC%2BC38XmvVeltL4%3D10.3109/13685538.2011.63123022439807 MorgentalerAGoodbye androgen hypothesis, hello saturation modelEur Urol20126276576710.1016/j.eururo.2012.06.02722728116 SjöströmLPeltonenMJacobsonPAhlinSAndersson-AssarssonJAnvedenÅAssociation of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complicationsJAMA20143112297230410.1001/jama.2014.598824915261 AllanCAMcLachlanRIAndrogens and obesityCurr Opin Endocrinol Diabetes Obes2010172242321:CAS:528:DC%2BC3cXltFKgtL0%3D10.1097/MED.0b013e3283398ee220418719 KheraMCrawfordDMoralesASaloniaAMorgentalerAA new era of testosterone and prostate cancer: from physiology to clinical implicationsEur Urol2014651151231:CAS:528:DC%2BC3sXhsVSku7jI10.1016/j.eururo.2013.08.01524011426 WaddenTAVictoriaLWMoranCHBailerBALifestyle modification for obesity: new developments in diet, physical activity, and behavior therapyCirculation2012125157117010.1161/CIRCULATIONAHA.111.039453 PelliteroSOlaizolaIAlastrueAMartínezEGranadaMLBalibreaJMHypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgeryObes Surg2012221835184210.1007/s11695-012-0734-922923309 KapoorDGoodwinEChannerKSJonesTHTestosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetesEur J Endocrinol20061548999061:CAS:528:DC%2BD28XmsVKqsrw%3D10.1530/eje.1.0216616728551 BhattacharyaRKKheraMBlickGKushnerHNguyenDMinerMMEffect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)BMC Endocr Disord201111181:CAS:528:DC%2BC3MXhsV2lurnP10.1186/1472-6823-11-18220446613217857 BehreHMTammelaTLArverSTolráJRBonifacioVLamcheMA randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-upAging Male2012151982071:CAS:528:DC%2BC38Xhs1GlsLbJ10.3109/13685538.2012.69956222834649 SaadFYassinAHaiderADorosGGoorenLElderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger menKorean J Urol20155631031710.4111/kju.2015.56.4.310258740454392031 NauckMFridAHermansenKThomsenABDuringMShahNLong-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 studyDiabetes Obes Metab2013152042121:CAS:528:DC%2BC3sXhs1aqurs%3D10.1111/dom.1201222985213 CharakidaMKhanTJohnsonWFinerNWoodsideJWhincupPHLifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological studyLancet Diab Endocrinol2014264865410.1016/S2213-8587(14)70103-2 BrethauerSAAminianARomero-TalamásHBatayyahEMackeyJKennedyLCan diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitusAnn Surg201325862863724018646 FinkelsteinJSLeeHBurnett-BowieS-APallaisJCYuEWBorgesLFGonadal steroids and body composition, strength, and sexual function in menN Engl J Med2013369101110221:CAS:528:DC%2BC3sXhsFGktr7F10.1056/NEJMoa1206168240248384142768 GarciaJASanchezPEFraileCEscovarPTestosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors aloneAndrologia2011432932961:CAS:528:DC%2BC3MXhtlChu7zN10.1111/j.1439-0272.2009.00991.x21919947 BrayGAWhy do we need drugs to treat the patient with obesity?Obesity (Silver Spring)20132189389910.1002/oby.20394 FrancomanoDLenziAAversaAEffects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndromeInt J Endocrinol2014201452747010.1155/2014/527470246885423945028 SaadFAversaAIsidoriAMGoorenLJTestosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a reviewCurr Diabetes Rev20128131143 G Yu (BFijo2015139_CR48) 2011; 8 F Saad (BFijo2015139_CR46) 2015; 56 L Sjöström (BFijo2015139_CR12) 2014; 311 EA Finkelstein (BFijo2015139_CR7) 2008; 16 L Sjöström (BFijo2015139_CR9) 2012; 307 A Aversa (BFijo2015139_CR21) 2010; 7 A Aversa (BFijo2015139_CR22) 2012; 15 RR Wing (BFijo2015139_CR14) 2010; 170 D Francomano (BFijo2015139_CR26) 2014; 37 SE Borst (BFijo2015139_CR27) 2014; 306 PA Dyson (BFijo2015139_CR18) 2010; 12 CJ Li (BFijo2015139_CR55) 2014; 13 A Morgentaler (BFijo2015139_CR60) 2015; 90 PMG Bouloux (BFijo2015139_CR47) 2013; 16 JS Finkelstein (BFijo2015139_CR24) 2013; 369 S Pellitero (BFijo2015139_CR20) 2012; 22 CA Allan (BFijo2015139_CR44) 2010; 17 F Zoicas (BFijo2015139_CR53) 2013; 168 DH Ryan (BFijo2015139_CR3) 2013; 15 G Hackett (BFijo2015139_CR40) 2014; 68 TA Wadden (BFijo2015139_CR16) 2012; 125 B Calderón (BFijo2015139_CR52) 2014; 24 F Saad (BFijo2015139_CR35) 2013; 21 SH Chang (BFijo2015139_CR15) 2014; 149 KM Gadde (BFijo2015139_CR51) 2014; 15 AM Traish (BFijo2015139_CR49) 2014; 21 M Charakida (BFijo2015139_CR4) 2014; 2 S Adabag (BFijo2015139_CR6) 2015; 101 HM Behre (BFijo2015139_CR23) 2012; 15 A Morgentaler (BFijo2015139_CR57) 2012; 62 A Yassin (BFijo2015139_CR38) 2013; 3 BFijo2015139_CR1 DE Arterburn (BFijo2015139_CR13) 2015; 313 VA Moyer (BFijo2015139_CR17) 2012; 157 M Nauck (BFijo2015139_CR54) 2013; 15 SY Kalinchenko (BFijo2015139_CR33) 2010; 73 A Haider (BFijo2015139_CR56) 2015; 193 D Kapoor (BFijo2015139_CR29) 2006; 154 RK Bhattacharya (BFijo2015139_CR42) 2012; 7 JA Garcia (BFijo2015139_CR43) 2011; 43 D Francomano (BFijo2015139_CR25) 2014; 2014 F Saad (BFijo2015139_CR45) 2012; 8 G Hackett (BFijo2015139_CR39) 2014; 11 AE Heufelder (BFijo2015139_CR32) 2009; 30 GA Bray (BFijo2015139_CR2) 2013; 21 K Johansson (BFijo2015139_CR5) 2014; 99 A Haider (BFijo2015139_CR37) 2014; 8 D Kapoor (BFijo2015139_CR28) 2007; 30 A Haider (BFijo2015139_CR36) 2014; 2014 M Khera (BFijo2015139_CR58) 2014; 65 L Sjöström (BFijo2015139_CR8) 2007; 357 A Morgentaler (BFijo2015139_CR59) 2009; 55 C Pexman-Fieth (BFijo2015139_CR31) 2014; 17 A Astrup (BFijo2015139_CR50) 2012; 36 SA Brethauer (BFijo2015139_CR19) 2013; 258 Diabetes Prevention Program Research Group (BFijo2015139_CR11) 2009; 374 M Zitzmann (BFijo2015139_CR34) 2013; 10 RK Bhattacharya (BFijo2015139_CR41) 2011; 11 J Svartberg (BFijo2015139_CR30) 2008; 20 LM Carlsson (BFijo2015139_CR10) 2012; 367 21844879 - Int J Obes (Lond). 2012 Jun;36(6):843-54 23512691 - Obesity (Silver Spring). 2013 Oct;21(10):1975-81 22439807 - Aging Male. 2012 Jun;15(2):96-102 20646185 - J Sex Med. 2010 Oct;7(10):3495-503 24018646 - Ann Surg. 2013 Oct;258(4):628-36; discussion 636-7 19878986 - Lancet. 2009 Nov 14;374(9702):1677-86 24011426 - Eur Urol. 2014 Jan;65(1):115-23 22834649 - Aging Male. 2012 Dec;15(4):198-207 24355040 - Int J Clin Pract. 2014 Feb;68(2):203-15 22956867 - Clin Interv Aging. 2012;7:321-30 24352617 - JAMA Surg. 2014 Mar;149(3):275-87 24915261 - JAMA. 2014 Jun 11;311(22):2297-304 20876408 - Arch Intern Med. 2010 Sep 27;170(17):1566-75 18480825 - Int J Impot Res. 2008 Jul-Aug;20(4):378-87 17392552 - Diabetes Care. 2007 Apr;30(4):911-7 22913680 - N Engl J Med. 2012 Aug 23;367(8):695-704 24856161 - Lancet Diabetes Endocrinol. 2014 Aug;2(8):648-54 24980615 - J Urol. 2015 Jan;193(1):80-6 24639122 - J Endocrinol Invest. 2014 Apr;37(4):401-11 24308723 - J Sex Med. 2014 Mar;11(3):840-56 25636998 - Mayo Clin Proc. 2015 Feb;90(2):224-51 23520198 - Obesity (Silver Spring). 2013 May;21(5):893-9 25874045 - Korean J Urol. 2015 Apr;56(4):310-7 21919947 - Andrologia. 2011 Oct;43(5):293-6 24688542 - Int J Endocrinol. 2014;2014:527470 22733087 - Ann Intern Med. 2012 Sep 4;157(5):373-8 25091355 - Obes Res Clin Pract. 2014 Jul-Aug;8(4):e339-49 24498905 - Cardiovasc Diabetol. 2014;13:36 17715408 - N Engl J Med. 2007 Aug 23;357(8):741-52 24664512 - Obes Surg. 2014 Oct;24(10):1686-92 24326421 - Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E433-42 22268394 - Curr Diabetes Rev. 2012 Mar;8(2):131-43 18838208 - Eur Urol. 2009 Feb;55(2):310-20 23392214 - Eur J Endocrinol. 2013 May;168(5):699-706 22812645 - J Sex Med. 2013 Feb;10(2):579-88 20880340 - Diabetes Obes Metab. 2010 Nov;12(11):941-6 24738000 - Int J Endocrinol. 2014;2014:683515 16728551 - Eur J Endocrinol. 2006 Jun;154(6):899-906 22215166 - JAMA. 2012 Jan 4;307(1):56-65 22923309 - Obes Surg. 2012 Dec;22(12):1835-42 23581697 - Aging Male. 2013 Jun;16(2):38-47 18535543 - Obesity (Silver Spring). 2008 Aug;16(8):1843-8 23625271 - Curr Hypertens Rep. 2013 Jun;15(3):182-9 20418719 - Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):224-32 20718771 - Clin Endocrinol (Oxf). 2010 Nov;73(5):602-12 22392863 - Circulation. 2012 Mar 6;125(9):1157-70 22044661 - BMC Endocr Disord. 2011 Nov 01;11:18 25410499 - Heart. 2015 Feb;101(3):215-21 22985213 - Diabetes Obes Metab. 2013 Mar;15(3):204-12 24274081 - Aging Male. 2014 Mar;17(1):1-11 22728116 - Eur Urol. 2012 Nov;62(5):765-7 25961342 - Horm Mol Biol Clin Investig. 2011 Oct 1;8(1):425-30 24163704 - Clin Obes. 2013 Jun;3(3-4):73-83 24548209 - Expert Opin Pharmacother. 2014 Apr;15(6):809-22 24024838 - N Engl J Med. 2013 Sep 12;369(11):1011-22 24172297 - Am J Clin Nutr. 2014 Jan;99(1):14-23 25105998 - Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):313-22 25562267 - JAMA. 2015 Jan 6;313(1):62-70 19578132 - J Androl. 2009 Nov-Dec;30(6):726-33 |
| References_xml | – reference: MoyerVAScreening for and management of obesity in adults: U.S. Preventive Services Task Force RecommendationAnn Intern Med201215737337822733087 – reference: AversaABruzzichesRFrancomanoDGrecoEAFornariRDi LuigiLEffects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled studyAging Male201215961021:CAS:528:DC%2BC38XmvVeltL4%3D10.3109/13685538.2011.63123022439807 – reference: HeufelderAESaadFBunckMCGoorenLFifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosteroneJ Androl2009307267331:CAS:528:DC%2BD1MXhsVeru73N10.2164/jandrol.108.00700519578132 – reference: FrancomanoDLenziAAversaAEffects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndromeInt J Endocrinol2014201452747010.1155/2014/527470246885423945028 – reference: BrethauerSAAminianARomero-TalamásHBatayyahEMackeyJKennedyLCan diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitusAnn Surg201325862863724018646 – reference: SvartbergJAgledahlIFigenschauYSildnesTWaterlooKJordeRTestosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hipInt J Impot Res2008203783871:CAS:528:DC%2BD1cXosVyiur0%3D10.1038/ijir.2008.1918480825 – reference: ZoicasFDrosteMMayrBBuchfelderMSchöflCGLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine casesEur J Endocrinol20131686997061:CAS:528:DC%2BC3sXotFansbg%3D10.1530/EJE-12-099723392214 – reference: SjöströmLPeltonenMJacobsonPSjöströmCDKarasonKWedelHBariatric surgery and long-term cardiovascular eventsJAMA2012307566510.1001/jama.2011.191422215166 – reference: SaadFHaiderADorosGTraishALong-term treatment of hypogonadal men with testosterone produces substantial and sustained weight lossObesity (Silver Spring)201321197519811:CAS:528:DC%2BC3sXhs1SmtLfJ10.1002/oby.20407 – reference: KalinchenkoSYTishovaYAMskhalayaGJGoorenLJGGiltayEJSaadFEffects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow studyClin Endocrinol (Oxf)2010736026121:CAS:528:DC%2BC3cXhsVagtLnL10.1111/j.1365-2265.2010.03845.x – reference: ArterburnDEOlsenMKSmithVALivingstonEHVan ScoyocLYancyWSJrAssociation between bariatric surgery and long-term survivalJAMA201531362701:CAS:528:DC%2BC2MXit1Onsbc%3D10.1001/jama.2014.1696825562267 – reference: NauckMFridAHermansenKThomsenABDuringMShahNLong-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 studyDiabetes Obes Metab2013152042121:CAS:528:DC%2BC3sXhs1aqurs%3D10.1111/dom.1201222985213 – reference: DysonPAThe therapeutics of lifestyle management on obesityDiabetes Obes Metab2010129419461:STN:280:DC%2BC3cfmtFSqtw%3D%3D10.1111/j.1463-1326.2010.01256.x20880340 – reference: MorgentalerATraishAMShifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growthEur Urol20095531032010.1016/j.eururo.2008.09.02418838208 – reference: Look AHEAD Research GroupLook AHEAD Research GroupWingRRLong-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trialArch Intern Med201017015661575 – reference: TraishAMTestosterone and weight loss: the evidenceCurr Opin Endocrinol Diabetes Obes2014213133221:CAS:528:DC%2BC2cXhsVOntLjO10.1097/MED.0000000000000086251059984154787 – reference: BoulouxPMGLegrosJJElbersJMHGeurtsTBPKaspersMJGHMeehanAGfor the Study 43203 Investigators. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging studyAging Male20131638471:CAS:528:DC%2BC3sXotFymsrs%3D10.3109/13685538.2013.77342023581697 – reference: HackettGColeNBhartiaMKennedyDRajuJWilkinsonPTestosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST StudyJ Sex Med2014118408561:CAS:528:DC%2BC2cXjvVyntrk%3D10.1111/jsm.1240424308723 – reference: Diabetes Prevention Program Research Group10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyLancet20093741677168610.1016/S0140-6736(09)61457-43135022 – reference: Dobbs R, Sawers C, Thompson F, Manyika J, Woetzel J, Child P et al Overcoming obesity: an initial economic analysis executive summary. McKinsey Global Institute November 2014. – reference: LiCJYuQYuPYuTLZhangQMLuSYuDMChanges in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patientsCardiovasc Diabetol2014133610.1186/1475-2840-13-36244989053923001 – reference: AversaABruzzichesRFrancomanoDRosanoGIsidoriAMLenziAEffects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled studyJ Sex Med20107349535031:CAS:528:DC%2BC3cXhsFemu7bE10.1111/j.1743-6109.2010.01931.x20646185 – reference: SaadFAversaAIsidoriAMGoorenLJTestosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a reviewCurr Diabetes Rev201281311431:CAS:528:DC%2BC38Xjs1Kmu7s%3D10.2174/157339912799424573222683943296126 – reference: AstrupACarraroRFinerNHarperAKunesovaMLeanMENN8022-1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInt J Obes (Lond)2012368438541:CAS:528:DC%2BC38Xos1Wkurs%3D10.1038/ijo.2011.158 – reference: AdabagSHuxleyRRLopezFLChenLYSotoodehniaNSiscovickDObesity related risk of sudden cardiac death in the atherosclerosis risk in communities studyHeart20151012152211:CAS:528:DC%2BC2MXjslGju7k%3D10.1136/heartjnl-2014-30623825410499 – reference: FrancomanoDBruzzichesRBarbaroGLenziAAversaAEffects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot studyJ Endocrinol Invest2014374014111:CAS:528:DC%2BC28Xhsl2isbY%3D10.1007/s40618-014-0066-924639122 – reference: HaiderAZitzmannMDorosGIsbarnHHammererPYassinAIncidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registriesJ Urol2015193808610.1016/j.juro.2014.06.07124980615 – reference: KheraMCrawfordDMoralesASaloniaAMorgentalerAA new era of testosterone and prostate cancer: from physiology to clinical implicationsEur Urol2014651151231:CAS:528:DC%2BC3sXhsVSku7jI10.1016/j.eururo.2013.08.01524011426 – reference: HaiderAYassinADorosGSaadFEffects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetesInt J Endocrinol20142014683515247380003967627 – reference: ZitzmannMMatternAHanischJGoorenLJonesHMaggiMIPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 menJ Sex Med2013105795881:CAS:528:DC%2BC3sXjsVWhtLs%3D10.1111/j.1743-6109.2012.02853.x22812645 – reference: JohanssonKNeoviusMHemmingssonEEffects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trialsAm J Clin Nutr20149914231:CAS:528:DC%2BC2cXislantQ%3D%3D10.3945/ajcn.113.07005224172297 – reference: BhattacharyaRKKheraMBlickGKushnerHNguyenDMinerMMEffect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)BMC Endocr Disord201111181:CAS:528:DC%2BC3MXhsV2lurnP10.1186/1472-6823-11-18220446613217857 – reference: CharakidaMKhanTJohnsonWFinerNWoodsideJWhincupPHLifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological studyLancet Diab Endocrinol2014264865410.1016/S2213-8587(14)70103-2 – reference: WaddenTAVictoriaLWMoranCHBailerBALifestyle modification for obesity: new developments in diet, physical activity, and behavior therapyCirculation2012125157117010.1161/CIRCULATIONAHA.111.039453 – reference: HaiderASaadFDorosGGoorenLHypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational studyObes Res Clin Pract20148e339e34910.1016/j.orcp.2013.10.00525091355 – reference: GarciaJASanchezPEFraileCEscovarPTestosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors aloneAndrologia2011432932961:CAS:528:DC%2BC3MXhtlChu7zN10.1111/j.1439-0272.2009.00991.x21919947 – reference: KapoorDGoodwinEChannerKSJonesTHTestosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetesEur J Endocrinol20061548999061:CAS:528:DC%2BD28XmsVKqsrw%3D10.1530/eje.1.0216616728551 – reference: KapoorDAldredHClarkSChannerKSJonesTHClinical and biochemical assessment of hypogonadism in men with type 2 diabetesDiabetes Care2007309119171:CAS:528:DC%2BD2sXkvVOgu7g%3D10.2337/dc06-142617392552 – reference: YuGTraishAInduced testosterone deficiency: from clinical presentation of fatigue, erectile dysfunction and muscle atrophy to insulin resistance and diabetesHorm Mol Biol Clin Invest201184254301:CAS:528:DC%2BC3sXhtFaksrbN – reference: BorstSEYarrowJFConoverCFNseyoUMeulemanJRLipinskaJAMusculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trialAm J Physiol Endocrinol Metab2014306E433E4421:CAS:528:DC%2BC2cXjs1yntbo%3D10.1152/ajpendo.00592.201324326421 – reference: MorgentalerAGoodbye androgen hypothesis, hello saturation modelEur Urol20126276576710.1016/j.eururo.2012.06.02722728116 – reference: SaadFYassinAHaiderADorosGGoorenLElderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger menKorean J Urol20155631031710.4111/kju.2015.56.4.310258740454392031 – reference: AllanCAMcLachlanRIAndrogens and obesityCurr Opin Endocrinol Diabetes Obes2010172242321:CAS:528:DC%2BC3cXltFKgtL0%3D10.1097/MED.0b013e3283398ee220418719 – reference: BehreHMTammelaTLArverSTolráJRBonifacioVLamcheMA randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-upAging Male2012151982071:CAS:528:DC%2BC38Xhs1GlsLbJ10.3109/13685538.2012.69956222834649 – reference: HackettGColeNBhartiaMKennedyDRajuJWilkinsonPThe response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study)Int J Clin Pract2014682032151:CAS:528:DC%2BC2cXhsF2rtLo%3D10.1111/ijcp.1223524355040 – reference: FinkelsteinEATrogdonJGBrownDSAllaireBTDelleaPSKamal-BahlSJThe lifetime medical cost burden of overweight and obesity: implications for obesity preventionObesity (Silver Spring)2008161843184810.1038/oby.2008.290 – reference: GaddeKMCurrent pharmacotherapy for obesity: extrapolation of clinical trials data to practiceExpert Opin Pharmacother2014158098221:CAS:528:DC%2BC2cXkvVyrtrc%3D10.1517/14656566.2014.89059024548209 – reference: CarlssonLMPeltonenMAhlinSAnvedenÅBouchardCCarlssonBBariatric surgery and prevention of type 2 diabetes in Swedish obese subjectsN Engl J Med20123676957041:CAS:528:DC%2BC38XhtlSlt7%2FN10.1056/NEJMoa111208222913680 – reference: ChangSHStollCRSongJVarelaJEEagonCJColditzGAThe effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012JAMA Surg201414927528710.1001/jamasurg.2013.3654243526173962512 – reference: SjöströmLNarbroKSjöströmCDKarasonKLarssonBWedelHSwedish obese subjects study. Effect of bariatric surgery on mortality in Swedish obese subjectsN Engl J Med200735774177210.1056/NEJMoa06625417715408 – reference: SjöströmLPeltonenMJacobsonPAhlinSAndersson-AssarssonJAnvedenÅAssociation of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complicationsJAMA20143112297230410.1001/jama.2014.598824915261 – reference: BhattacharyaRKKheraMBlickGKushnerHMinerMMTestosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS)Clin Interv Aging201273213301:CAS:528:DC%2BC38XhsVSjtLnK10.2147/CIA.S32036229568673430096 – reference: YassinADorosGTestosterone therapy in hypogonadal men results in sustained and clinically meaningful weight lossClin Obes20133738310.1111/cob.12022241637043799011 – reference: MorgentalerAMinerMMCaliberMGuayATKheraMTraishAMTestosterone therapy and cardiovascular risk: advances and controversiesMayo Clin Proc2015902242511:CAS:528:DC%2BC2MXhs1ejurY%3D10.1016/j.mayocp.2014.10.01125636998 – reference: FinkelsteinJSLeeHBurnett-BowieS-APallaisJCYuEWBorgesLFGonadal steroids and body composition, strength, and sexual function in menN Engl J Med2013369101110221:CAS:528:DC%2BC3sXhsFGktr7F10.1056/NEJMoa1206168240248384142768 – reference: PelliteroSOlaizolaIAlastrueAMartínezEGranadaMLBalibreaJMHypogonadotropic hypogonadism in morbidly obese males is reversed after bariatric surgeryObes Surg2012221835184210.1007/s11695-012-0734-922923309 – reference: BrayGAWhy do we need drugs to treat the patient with obesity?Obesity (Silver Spring)20132189389910.1002/oby.20394 – reference: CalderónBGaldónACalañasAPeromingoRGalindoJGarcía-MorenoFEffects of bariatric surgery on male obesity-associated secondary hypogonadism: comparison of laparoscopic gastric bypass with restrictive proceduresObes Surg2014241686169210.1007/s11695-014-1233-y24664512 – reference: RyanDHBrayGAPharmacologic treatment options for obesity: what is old is new againCurr Hypertens Rep2013151821891:CAS:528:DC%2BC3sXnsFGjtrc%3D10.1007/s11906-013-0343-623625271 – reference: Pexman-FiethCBehreHMMoralesAKan-DobroskyNMillerMGA 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gelAging Male2014171111:CAS:528:DC%2BC2cXjt1antLk%3D10.3109/13685538.2013.85811324274081 – volume: 30 start-page: 911 year: 2007 ident: BFijo2015139_CR28 publication-title: Diabetes Care doi: 10.2337/dc06-1426 – volume: 11 start-page: 840 year: 2014 ident: BFijo2015139_CR39 publication-title: J Sex Med doi: 10.1111/jsm.12404 – volume: 8 start-page: 425 year: 2011 ident: BFijo2015139_CR48 publication-title: Horm Mol Biol Clin Invest – volume: 21 start-page: 893 year: 2013 ident: BFijo2015139_CR2 publication-title: Obesity (Silver Spring) doi: 10.1002/oby.20394 – volume: 13 start-page: 36 year: 2014 ident: BFijo2015139_CR55 publication-title: Cardiovasc Diabetol doi: 10.1186/1475-2840-13-36 – ident: BFijo2015139_CR1 – volume: 15 start-page: 182 year: 2013 ident: BFijo2015139_CR3 publication-title: Curr Hypertens Rep doi: 10.1007/s11906-013-0343-6 – volume: 170 start-page: 1566 year: 2010 ident: BFijo2015139_CR14 publication-title: Arch Intern Med – volume: 68 start-page: 203 year: 2014 ident: BFijo2015139_CR40 publication-title: Int J Clin Pract doi: 10.1111/ijcp.12235 – volume: 7 start-page: 321 year: 2012 ident: BFijo2015139_CR42 publication-title: Clin Interv Aging doi: 10.2147/CIA.S32036 – volume: 15 start-page: 809 year: 2014 ident: BFijo2015139_CR51 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2014.890590 – volume: 65 start-page: 115 year: 2014 ident: BFijo2015139_CR58 publication-title: Eur Urol doi: 10.1016/j.eururo.2013.08.015 – volume: 56 start-page: 310 year: 2015 ident: BFijo2015139_CR46 publication-title: Korean J Urol doi: 10.4111/kju.2015.56.4.310 – volume: 307 start-page: 56 year: 2012 ident: BFijo2015139_CR9 publication-title: JAMA doi: 10.1001/jama.2011.1914 – volume: 2 start-page: 648 year: 2014 ident: BFijo2015139_CR4 publication-title: Lancet Diab Endocrinol doi: 10.1016/S2213-8587(14)70103-2 – volume: 15 start-page: 204 year: 2013 ident: BFijo2015139_CR54 publication-title: Diabetes Obes Metab doi: 10.1111/dom.12012 – volume: 73 start-page: 602 year: 2010 ident: BFijo2015139_CR33 publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2010.03845.x – volume: 43 start-page: 293 year: 2011 ident: BFijo2015139_CR43 publication-title: Andrologia doi: 10.1111/j.1439-0272.2009.00991.x – volume: 157 start-page: 373 year: 2012 ident: BFijo2015139_CR17 publication-title: Ann Intern Med doi: 10.7326/0003-4819-157-5-201209040-00475 – volume: 15 start-page: 198 year: 2012 ident: BFijo2015139_CR23 publication-title: Aging Male doi: 10.3109/13685538.2012.699562 – volume: 369 start-page: 1011 year: 2013 ident: BFijo2015139_CR24 publication-title: N Engl J Med doi: 10.1056/NEJMoa1206168 – volume: 2014 start-page: 683515 year: 2014 ident: BFijo2015139_CR36 publication-title: Int J Endocrinol – volume: 10 start-page: 579 year: 2013 ident: BFijo2015139_CR34 publication-title: J Sex Med doi: 10.1111/j.1743-6109.2012.02853.x – volume: 55 start-page: 310 year: 2009 ident: BFijo2015139_CR59 publication-title: Eur Urol doi: 10.1016/j.eururo.2008.09.024 – volume: 21 start-page: 1975 year: 2013 ident: BFijo2015139_CR35 publication-title: Obesity (Silver Spring) doi: 10.1002/oby.20407 – volume: 154 start-page: 899 year: 2006 ident: BFijo2015139_CR29 publication-title: Eur J Endocrinol doi: 10.1530/eje.1.02166 – volume: 311 start-page: 2297 year: 2014 ident: BFijo2015139_CR12 publication-title: JAMA doi: 10.1001/jama.2014.5988 – volume: 16 start-page: 1843 year: 2008 ident: BFijo2015139_CR7 publication-title: Obesity (Silver Spring) doi: 10.1038/oby.2008.290 – volume: 306 start-page: E433 year: 2014 ident: BFijo2015139_CR27 publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00592.2013 – volume: 168 start-page: 699 year: 2013 ident: BFijo2015139_CR53 publication-title: Eur J Endocrinol doi: 10.1530/EJE-12-0997 – volume: 17 start-page: 1 year: 2014 ident: BFijo2015139_CR31 publication-title: Aging Male doi: 10.3109/13685538.2013.858113 – volume: 101 start-page: 215 year: 2015 ident: BFijo2015139_CR6 publication-title: Heart doi: 10.1136/heartjnl-2014-306238 – volume: 36 start-page: 843 year: 2012 ident: BFijo2015139_CR50 publication-title: Int J Obes (Lond) doi: 10.1038/ijo.2011.158 – volume: 12 start-page: 941 year: 2010 ident: BFijo2015139_CR18 publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2010.01256.x – volume: 367 start-page: 695 year: 2012 ident: BFijo2015139_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa1112082 – volume: 99 start-page: 14 year: 2014 ident: BFijo2015139_CR5 publication-title: Am J Clin Nutr doi: 10.3945/ajcn.113.070052 – volume: 8 start-page: 131 year: 2012 ident: BFijo2015139_CR45 publication-title: Curr Diabetes Rev doi: 10.2174/157339912799424573 – volume: 37 start-page: 401 year: 2014 ident: BFijo2015139_CR26 publication-title: J Endocrinol Invest doi: 10.1007/s40618-014-0066-9 – volume: 7 start-page: 3495 year: 2010 ident: BFijo2015139_CR21 publication-title: J Sex Med doi: 10.1111/j.1743-6109.2010.01931.x – volume: 24 start-page: 1686 year: 2014 ident: BFijo2015139_CR52 publication-title: Obes Surg doi: 10.1007/s11695-014-1233-y – volume: 8 start-page: e339 year: 2014 ident: BFijo2015139_CR37 publication-title: Obes Res Clin Pract doi: 10.1016/j.orcp.2013.10.005 – volume: 90 start-page: 224 year: 2015 ident: BFijo2015139_CR60 publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2014.10.011 – volume: 374 start-page: 1677 year: 2009 ident: BFijo2015139_CR11 publication-title: Lancet doi: 10.1016/S0140-6736(09)61457-4 – volume: 21 start-page: 313 year: 2014 ident: BFijo2015139_CR49 publication-title: Curr Opin Endocrinol Diabetes Obes doi: 10.1097/MED.0000000000000086 – volume: 15 start-page: 96 year: 2012 ident: BFijo2015139_CR22 publication-title: Aging Male doi: 10.3109/13685538.2011.631230 – volume: 16 start-page: 38 year: 2013 ident: BFijo2015139_CR47 publication-title: Aging Male doi: 10.3109/13685538.2013.773420 – volume: 62 start-page: 765 year: 2012 ident: BFijo2015139_CR57 publication-title: Eur Urol doi: 10.1016/j.eururo.2012.06.027 – volume: 193 start-page: 80 year: 2015 ident: BFijo2015139_CR56 publication-title: J Urol doi: 10.1016/j.juro.2014.06.071 – volume: 11 start-page: 18 year: 2011 ident: BFijo2015139_CR41 publication-title: BMC Endocr Disord doi: 10.1186/1472-6823-11-18 – volume: 3 start-page: 73 year: 2013 ident: BFijo2015139_CR38 publication-title: Clin Obes doi: 10.1111/cob.12022 – volume: 149 start-page: 275 year: 2014 ident: BFijo2015139_CR15 publication-title: JAMA Surg doi: 10.1001/jamasurg.2013.3654 – volume: 357 start-page: 741 year: 2007 ident: BFijo2015139_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa066254 – volume: 313 start-page: 62 year: 2015 ident: BFijo2015139_CR13 publication-title: JAMA doi: 10.1001/jama.2014.16968 – volume: 125 start-page: 157 year: 2012 ident: BFijo2015139_CR16 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.039453 – volume: 2014 start-page: 527470 year: 2014 ident: BFijo2015139_CR25 publication-title: Int J Endocrinol doi: 10.1155/2014/527470 – volume: 30 start-page: 726 year: 2009 ident: BFijo2015139_CR32 publication-title: J Androl doi: 10.2164/jandrol.108.007005 – volume: 258 start-page: 628 year: 2013 ident: BFijo2015139_CR19 publication-title: Ann Surg doi: 10.1097/SLA.0b013e3182a5034b – volume: 20 start-page: 378 year: 2008 ident: BFijo2015139_CR30 publication-title: Int J Impot Res doi: 10.1038/ijir.2008.19 – volume: 17 start-page: 224 year: 2010 ident: BFijo2015139_CR44 publication-title: Curr Opin Endocrinol Diabetes Obes doi: 10.1097/MED.0b013e3283398ee2 – volume: 22 start-page: 1835 year: 2012 ident: BFijo2015139_CR20 publication-title: Obes Surg doi: 10.1007/s11695-012-0734-9 – reference: 24548209 - Expert Opin Pharmacother. 2014 Apr;15(6):809-22 – reference: 24018646 - Ann Surg. 2013 Oct;258(4):628-36; discussion 636-7 – reference: 22268394 - Curr Diabetes Rev. 2012 Mar;8(2):131-43 – reference: 20876408 - Arch Intern Med. 2010 Sep 27;170(17):1566-75 – reference: 25105998 - Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):313-22 – reference: 22956867 - Clin Interv Aging. 2012;7:321-30 – reference: 22923309 - Obes Surg. 2012 Dec;22(12):1835-42 – reference: 22834649 - Aging Male. 2012 Dec;15(4):198-207 – reference: 22215166 - JAMA. 2012 Jan 4;307(1):56-65 – reference: 22439807 - Aging Male. 2012 Jun;15(2):96-102 – reference: 16728551 - Eur J Endocrinol. 2006 Jun;154(6):899-906 – reference: 20880340 - Diabetes Obes Metab. 2010 Nov;12(11):941-6 – reference: 20646185 - J Sex Med. 2010 Oct;7(10):3495-503 – reference: 20718771 - Clin Endocrinol (Oxf). 2010 Nov;73(5):602-12 – reference: 25961342 - Horm Mol Biol Clin Investig. 2011 Oct 1;8(1):425-30 – reference: 23625271 - Curr Hypertens Rep. 2013 Jun;15(3):182-9 – reference: 25874045 - Korean J Urol. 2015 Apr;56(4):310-7 – reference: 25562267 - JAMA. 2015 Jan 6;313(1):62-70 – reference: 24352617 - JAMA Surg. 2014 Mar;149(3):275-87 – reference: 25636998 - Mayo Clin Proc. 2015 Feb;90(2):224-51 – reference: 24274081 - Aging Male. 2014 Mar;17(1):1-11 – reference: 24024838 - N Engl J Med. 2013 Sep 12;369(11):1011-22 – reference: 20418719 - Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):224-32 – reference: 23520198 - Obesity (Silver Spring). 2013 May;21(5):893-9 – reference: 24856161 - Lancet Diabetes Endocrinol. 2014 Aug;2(8):648-54 – reference: 22392863 - Circulation. 2012 Mar 6;125(9):1157-70 – reference: 22733087 - Ann Intern Med. 2012 Sep 4;157(5):373-8 – reference: 18535543 - Obesity (Silver Spring). 2008 Aug;16(8):1843-8 – reference: 25410499 - Heart. 2015 Feb;101(3):215-21 – reference: 24639122 - J Endocrinol Invest. 2014 Apr;37(4):401-11 – reference: 24011426 - Eur Urol. 2014 Jan;65(1):115-23 – reference: 23512691 - Obesity (Silver Spring). 2013 Oct;21(10):1975-81 – reference: 24163704 - Clin Obes. 2013 Jun;3(3-4):73-83 – reference: 24498905 - Cardiovasc Diabetol. 2014;13:36 – reference: 24915261 - JAMA. 2014 Jun 11;311(22):2297-304 – reference: 21844879 - Int J Obes (Lond). 2012 Jun;36(6):843-54 – reference: 23392214 - Eur J Endocrinol. 2013 May;168(5):699-706 – reference: 22728116 - Eur Urol. 2012 Nov;62(5):765-7 – reference: 18480825 - Int J Impot Res. 2008 Jul-Aug;20(4):378-87 – reference: 22812645 - J Sex Med. 2013 Feb;10(2):579-88 – reference: 24688542 - Int J Endocrinol. 2014;2014:527470 – reference: 24308723 - J Sex Med. 2014 Mar;11(3):840-56 – reference: 25091355 - Obes Res Clin Pract. 2014 Jul-Aug;8(4):e339-49 – reference: 21919947 - Andrologia. 2011 Oct;43(5):293-6 – reference: 19578132 - J Androl. 2009 Nov-Dec;30(6):726-33 – reference: 23581697 - Aging Male. 2013 Jun;16(2):38-47 – reference: 22913680 - N Engl J Med. 2012 Aug 23;367(8):695-704 – reference: 24172297 - Am J Clin Nutr. 2014 Jan;99(1):14-23 – reference: 22985213 - Diabetes Obes Metab. 2013 Mar;15(3):204-12 – reference: 24980615 - J Urol. 2015 Jan;193(1):80-6 – reference: 17392552 - Diabetes Care. 2007 Apr;30(4):911-7 – reference: 24326421 - Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E433-42 – reference: 24664512 - Obes Surg. 2014 Oct;24(10):1686-92 – reference: 24738000 - Int J Endocrinol. 2014;2014:683515 – reference: 24355040 - Int J Clin Pract. 2014 Feb;68(2):203-15 – reference: 18838208 - Eur Urol. 2009 Feb;55(2):310-20 – reference: 17715408 - N Engl J Med. 2007 Aug 23;357(8):741-52 – reference: 22044661 - BMC Endocr Disord. 2011 Nov 01;11:18 – reference: 19878986 - Lancet. 2009 Nov 14;374(9702):1677-86 |
| SSID | ssj0005502 ssj0033214 |
| Score | 2.5027552 |
| Snippet | Background/Objectives:
Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in... Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in hypogonadal men. This... BACKGROUND/OBJECTIVES: Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in... SUBJECTS/METHODS: From two independent observational registries we identified a total of 411 obese, hypogonadal men receiving TRT in urological clinics. The... Background/Objectives:Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL) in... Background/ Objectives: Long-term testosterone replacement therapy (TRT) up to 5 years has been shown to produce progressive and sustainable weight loss (WL)... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 162 |
| SubjectTerms | 692/163 692/699/2743/1526/1561 692/699/2743/393 692/700/2817 692/700/478/174 692/700/565/1331/238 Analysis Androgens - blood Androgens - therapeutic use Atherosclerosis Body mass index Care and treatment Complications and side effects Epidemiology Follow-Up Studies Gastrointestinal surgery Germany - epidemiology Health aspects Health Promotion and Disease Prevention Humans Hypogonadism - blood Hypogonadism - drug therapy Hypogonadism - metabolism Influence Internal Medicine Male Medicine Medicine & Public Health Men's Health Metabolic Diseases Middle Aged Mortality Obesity Obesity - drug therapy Obesity - metabolism Obesity - prevention & control Original original-article Prospective Studies Public Health Registries Risk Factors Testosterone Testosterone - blood Testosterone - therapeutic use Time Factors Treatment Outcome Waist Circumference - drug effects Weight Loss - drug effects |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgLguUVKDBIUA4oNLGdFxdUAVUXqT1RaW9R4jht0CpZSKoV_CP-JTOOk92soNf1JGvH43nY4-9j7HWmpB_FpXJLnmGC4mfCzQsfFx4vZBaHqFaGDOb0LDw5l18XwcJuuLW2rHKwicZQF42iPfJDdHMYXHMhvY-rHy6xRtHpqqXQuMluEXQZJV_RItqUeATeiCUliJFnQEVErx_YKnhPxIfVd7oG6AfvfeIM3_JPu1Z6y03tllDunKMa93R8j921cSUc9Ypwn93Q9Yw5nyvdwQFY8M8lnA3Y-zN2-9Seqs_YbBM7orDhPW8fsD89sHELTQnLpr5wyYjDWJgOtIMLHRHTENZCU2vAx9dmpxWyuoB1hhoEbfVbQ1WD9H24_LVqLjDyL7An-Ir-DU3PTACKwnjdwtydz-cf8OdxuxilqY4V6CYMdOsGiEyCOOqg7YsgH7Lz4y_fPp24ltjBVWHgd26UaILCUwUGowVP8rKQSaxyxTklrHlEkD5CZlwWiosoKHUR6dzDj50EHoabSjxiezWO6wkDHxOeEjMEJTIhtfDzRCgvjLl5Wx5xh70bpjNVFvWcyDeWqTl9F3GKk5_S5Kc4-Q57M0qverSP_8i9JM1I-7uqo5FIj6QknkYRhA57ayTITOD_qczedsBeE-DWRHJ_IonLW02bB-1LrXlp081icNirsZmepJK5WjdXRkaSCxHXyoSYUMaYZTnsca_Q47h5iM4MF7LDoomqjwIETD5tqatLA1BOAKSc-nYwLIqtrv_jcz69fozP2B2UtBtf-2yv-3mln2Mo2OUvzHr_C_3wXCA priority: 102 providerName: ProQuest |
| Title | Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies |
| URI | https://link.springer.com/article/10.1038/ijo.2015.139 https://www.ncbi.nlm.nih.gov/pubmed/26219417 https://www.proquest.com/docview/1755482340 https://www.proquest.com/docview/1754088730 https://www.proquest.com/docview/1765978882 https://pubmed.ncbi.nlm.nih.gov/PMC4722240 |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3ra9RAEB_6ABFE9HxF6zmC1g8aTXY3j_NbPVt6Qg8RC_ctJJukPTmSYlIO_Y_8L53ZPNocKn45wu3sZpPMzmN35jcAL2Kt3CDMtZ2LmBwUN5Z2krq08ESq4tAntjLFYE7m_vGp-rTwFlvwpsuFMUH7BtLSiOkuOuzd8htn6rneW7JYtmGXQds5gG_qT68COjynR46SXH-nw0AkHe-1Me-ODAdDDbTRpky-ppQ2AyY3Tk2NMjq6A7dbKxIPmnnfha2sGIH1cZnVuI8t1OcK5x3S_ghunLRn6CO41ezUYZOANILRleVInU3V8-oe_GpgjSssc1yVxZnNIhz7sHTk_VusuSwNIy2URYbUfW32WTEuUlzHxD9YLX9muCxQuS6e_7goz8juT2lmNEQzQtnUJUDNRnxW4cyezWbv6e9-s5ioOYoVOQ8G63WJXEqCK9Rh1YRA3ofTo8Ov02O7Letga99zazuYZAyEp1MyRVMxSfJUTUKdaCHYXU0CBvSRKhYq1UIGXp6lQZY49PInnkPGppYPYKeg53oE6JK7k5N_oGUsVSbdZCK144fCjJYEwoLX3eeNdIt5zqU3VpE5e5dhRMwQMTNExAwWvOypLxqsj7_QPWNOiZpM1V5ERAdKcZVG6fkWvDIULCTofjpucx1o1gy3NaDcG1DS4tbD5o4bo1a4VBFZfORnCqkcC573zdyTA-aKrLw0NIoViPwnjU_uZEg-lgUPGwbvn1v4pMpoGVsQDFi_J2BY8mFLsTw38OQMPyp4bvvdIrk29T-8zsf_S_gEbtJluwG2Bzv198vsKZmEdTKG7WAR0G84dcew--Fw_vnL2EiH3_9LYFs |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYALguUVKHSQaDmg0MR2XkgIVS3Vhnb31Eq9pYnjtItWyUJSrco_4sJvZCav7q6gt143E68dj-dhj7-PsXexkrbnZ8rMeIwJih0LM0ltXHg8lbHvolrVZDCjsTs8kd9OndM19qe7C0NllZ1NrA11WijaI99BN4fBNRfS-jL7YRJrFJ2udhQajVoc6qs5pmzl53Af53eL84Ovx3tDs2UVMJXr2JXpBZpw2FSKkVDKgyRLZeCrRHFO2VLiEZ6MkDGXqeLCczKdejqxdKoCx8JYRwls9w67K4XwCKvf31soKXGsHrtKEANQh8KIUYbTVt1bwt-ZfKdrh7bz0SaO8gV_uOoVFtziasnmyrlt7Q4PHrGHbRwLu43iPWZrOh8wY3-iK9iGFmx0CuMO63_A7o3aU_wBG1zHqihc86yXT9jvBki5hCKDaZGfm-Q0oC-EB9oxhoqIcAjbocg14OvzemcX4jyFeYwaC-Xkl4ZJDtK24eJqVpxjppFiT7CJpoWiYUIARWmDLiE0wzD8hD_329MoTXWzQDdvoJoXQOQVxIkHZVN0-ZSd3MqUP2PrOY7rBQMbE6wMMxIlYiG1sJNAKMv1ed1a4nGDfeimM1ItyjqRfUyj-rRf-BFOfkSTH-HkG2yrl5416CL_kdskzYiau7G9UYp2pSReSOG4BntfS5BZwv9TcXu7AntNAF9LkhtLkmhO1PLjTvui1pyV0fXiM9jb_jG9SSV6uS4uaxlJLkvcKONiAutjVmew541C9-PmLjpPNBwG85ZUvRcgIPTlJ_nkogZEJ8BTTn3b7hbFQtf_8Tlf3jzGTXZ_eDw6io7C8eEr9gDfajfdNth69fNSv8YwtEre1Gsf2NltG5u_zXeYMQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkCZeEJRbYLCDxMYDCk1s51IkhCZKtTBW8cCkvmWJ42xFVVJIpmr8I_4Cv45zcutFsLe9NieuHR-fi338fYy9ipS0PT9VZsojTFDsSJhxYuPC44mMfBfVqiKDORm7R6fy88SZbLE_7V0YKqtsbWJlqJNc0R55H90cBtdcSKufNmURX4ejD_MfJjFI0UlrS6dRq8ixvlpg-la8D4Y41_ucjz59-3hkNgwDpnIduzS9gSZMNpVgVJTwQZwmcuCrWHFOmVPsEbaMkBGXieLCc1KdeDq2dKIGjoVxjxLY7i122xPoNnEteRNvWV7iWB2OlSA2oBaRESMOp6nAt4Tfn36nK4i289YmvvIV37jpIVZc5Gb55sYZbuUaR_fY3SamhcNaCe-zLZ31mDGc6hIOoAEencG4xf3vsZ2T5kS_x3rLuBWFK8714gH7XYMqF5CnMMuzc5McCHRF8UC7x1ASKQ7hPOSZBnx9Ue3yQpQlsIhQe6GY_tIwzUDaNlxczfNzzDoS7Ak2UbeQ16wIoCiF0AUEZhAE7_DnbqsapamGFugWDpSLHIjIgvjxoKgLMB-y0xuZ8kdsO8NxPWFgY7KVYnaiRCSkFnY8EMpyfV61FnvcYG_a6QxVg7hOxB-zsDr5F36Ikx_S5Ic4-Qbb76TnNdLIf-T2SDPC-p5sZ6DCQymJI1I4rsFeVxJkovD_VNTctMBeE9jXmuTumiSaFrX-uNW-sDFtRbhciAZ72T2mN6lcL9P5ZSUjyX2Ja2VcTGZ9zPAM9rhW6G7c3EVHikbEYN6aqncCBIq-_iSbXlTg6AR-yqlvB-2iWOn6Pz7n0-vHuMd20MyEX4Lx8TN2B19q9t922Xb581I_x4i0jF9USx_Y2U3bmr9zxpyT |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+long-term+treatment+with+testosterone+on+weight+and+waist+size+in+411+hypogonadal+men+with+obesity+classes+I-III%3A+observational+data+from+two+registry+studies&rft.jtitle=International+Journal+of+Obesity&rft.au=Saad%2C+F&rft.au=Yassin%2C+A&rft.au=Doros%2C+G&rft.au=Haider%2C+A&rft.date=2016-01-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=0307-0565&rft.eissn=1476-5497&rft.volume=40&rft.issue=1&rft.spage=162&rft.epage=170&rft_id=info:doi/10.1038%2Fijo.2015.139&rft.externalDocID=10_1038_ijo_2015_139 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0307-0565&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0307-0565&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0307-0565&client=summon |